The ARMOR study is a phase 3, multinational clinical trial to evaluate the efficacy and safety of Aramchol™ for adults with NASH and liver fibrosis.
How did we get here?
In a multinational, placebo-controlled, Phase 2b ARREST study involving treatment for 52 weeks in 247 patients with NASH, Aramchol™ significantly reduced liver fat, improved liver histology, hepatic biochemistry and glycemic parameters with a favorable safety and tolerability profile.
Fast track designation
by the FDA
Conveninent one pill
twice a day
Innovative new molecule, tested in 9 clinical trials
For NASH resolution
& Fibrosis improvement
How does this trial work?
ARMOR is a double-Blind, Placebo-Controlled registrational Ph3 study testing whether an investigational medicine Aramchol™ is effective and safe for the treatment of NASH and fibrosis. The study has been initiated internationally early 2020 however due to the COVID-19 outbreak, an Open-Label Part was added to the ARMOR study to enable the existing study resources to be used efficiently during the COVID-19 pandemic, while enrollment in the Double-Blind, Placebo-Controlled Part is pending.
The Open-Label Part includes 150 subjects with NASH and liver fibrosis stage 1-3, who may or may not be overweight, and subjects with NASH who may or may not have Type 2 Diabetes Mellitus (T2DM) or be pre-diabetic. The Open-Label Part will provide important safety and PK data as well as obtain important data to help characterize the kinetics of histological outcomes of Aramchol™ and Non-Invasive Tests (NITs) for NASH associated with liver fibrosis after several time points (i.e., 24, 48 and 72 weeks). The Open-Label Part will continue for the same duration as the Randomized, Double-Blind, Placebo-Controlled Part once resumed.
In order to qualify for the study, you need to be 18 years or older and suffer from NASH with liver fibrosis. You will be evaluated for NASH using non-invasive methods and if found eligible, you will undergo a liver biopsy.
Once you have qualified for the study, you will be assigned either to a group that will receive Aramchol™ treatment or to a group that will receive a placebo (a pill that has no medical effect). You are twice as likely to receive Aramchol™ as the placebo in this study. During the study, your health will be followed closely for several years, through routine scheduled visits with your study doctor.
If you qualify and join the study, you may receive reimbursement for time and travel and the study drug will be provided at no cost to you.
Further information about the ARMOR Study can be found on ClinicalTrials.gov identifier: NCT04104321
Take a more active role in your health care
Gain immediate access to a new investigative treatment
Receive free study-related care from a local specialist
Have a home where your medical needsare appreciated
Health insurance not required
Receive compensation for your time and travel
For Medical & Healthcare providers:email@example.com